CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?

CVS Health's second-quarter earnings estimates have been revised down by $0.11 to $1.47 per share, a projected 19.67% year-over-year decline, attributed to elevated medical costs, significant one-time legal and asset-related charges exceeding $1 billion, and increasing regulatory pressures impacting its PBM operations. Despite these near-term headwinds, which saw the stock underperform the S&P 500 in Q2, the company's strategic initiatives in Aetna's benefit redesigns, PBM cost management through Caremark's new models, and retail footprint optimization are expected to drive long-term growth and margin recovery, supporting its Zacks #2 (Buy) rating and consistent history of earnings beats.

Analysis

CVS Health presents a complex investment case ahead of its second-quarter earnings, characterized by significant near-term headwinds that have prompted downward earnings revisions, juxtaposed with strategic initiatives aimed at long-term recovery and growth. Analysts have lowered Q2 earnings estimates from $1.58 to $1.47 per share, implying a substantial 19.67% year-over-year decline. This revision is driven by persistent margin pressure from elevated Medicare Advantage medical costs, over $1 billion in one-time charges from legal verdicts and asset losses, and mounting regulatory scrutiny, exemplified by new Arkansas legislation forcing over 20 pharmacy closures. Despite these challenges and the stock's 2.5% Q2 gain underperforming the S&P 500's 10.7% rise, the company has demonstrated resilience. It has a strong track record of beating consensus estimates, with an average positive earnings surprise of 18.08% over the last four quarters. Furthermore, strategic actions are underway across its segments: the Healthcare Benefits unit (Aetna) is being repositioned for a 2025 margin recovery through benefit redesigns; the Health Services segment (Caremark) is enhancing transparency and managing costs with new PBM models covering over 75% of commercial members; and the retail arm is benefiting from footprint optimization. The stock's valuation, with a forward P/E of 9.24X, remains at a discount to key peer UnitedHealth Group (12.27X), which saw its stock decline 40% in the same period.

Key Decisions for Investors

• Investors should scrutinize the upcoming Q2 results for evidence that strategic pricing and benefit redesigns are successfully mitigating the high medical costs in the Aetna business, as this remains the primary drag on profitability.
• Given the stock's valuation discount to UNH and its relative price outperformance, the current weakness could present a strategic entry point, provided management demonstrates tangible progress on its turnaround initiatives and cost-control measures.
• The forecasted 19.67% YoY earnings decline must be weighed against the company's consistent history of significant earnings beats, suggesting investors should be prepared for potential volatility and a possible positive surprise relative to the lowered consensus.
• Monitor regulatory developments closely, particularly concerning PBMs, as actions like Arkansas's HB1150 represent a material risk to the Health Services segment's operating model and future profitability.